|Bid||1,427.20 x 0|
|Ask||1,427.40 x 0|
|Day's range||1,400.00 - 1,437.80|
|52-week range||1,371.00 - 2,746.59|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||12.61|
|Earnings date||02 Nov 2022|
|Forward dividend & yield||0.86 (6.09%)|
|Ex-dividend date||18 Aug 2022|
|1y target est||N/A|
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.